Consumers with opioid addiction who engaged with Pear Therapeutics’ reSET-O® for 12 weeks of treatment had a 34% lower incidence of all-cause hospital encounters over the next nine months following treatment compared to those who were prescribed but did not engage with reSET-O. reSET-O is a prescription digital therapeutic (PDT) approved by the U.S Food and Drug Administration (FDA) for treatment of opioid use disorder in conjunction with medication such as buprenorphine. Over the nine months after being prescribed re-SET-O, those who engaged with re-SET-O had 0.732 unique hospital encounters . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!